Let's see what I can remember. Our technology has an advantage...

Let's see what I can remember.

Our technology has an advantage in that it is able to process small batches of plasma, at lower cost than the current process used in developed countries, while its being completely disposable means that there is no risk of contamination from one batch to another, should one batch be contaminated. This is the main reason why the big fractionators aren't interested in processing product from outside the developed world: with no way of controlling the collection process in developing countries to ensure non-contamination, and no way of preventing cross contamination between batches. The Prime process addresses this.

The 'major Asian life sciences fund' we are negotiating with insists on its anonymity - this was the reason for the second announcement to market a couple of weeks ago that to most of us seemed to have no purpose (and still doesn't, as far as I can see). They are genuinely interested. Negotiations are coming down to brass tacks of what they will get for their investment. Interest from the 1% investors has risen on news that the life sciences fund is doing due diligence, as seen in the increase in the entry price for a parcel of shares (which I think went up a few percent). The expectation is that, while quite risk averse, they will jump in once the life sciences fund shows its hand.

The big hurdles for the near term are settling the funding arrangements, which should take about three months, and then the nine months to get cGMP certification. The Singaporeans seem keen to have us set up there, and the qualities of the facility mean that we should be able to get this done on time and without hitches.

The message overall was: there is demand in the region, esp. in India; there are investors who are interested but just need reassurance before they commit; the Singaporean regulators are happy for us to be there. If the life sciences fund signs up, many pieces will fall into place and we can begin moving forward to production in about two years.

Apparently a large Australian bio products processing company (I won't use their name but you can do the maths) won't be interested in what we do until our product is registered and we get regulatory approval. Plus they only do big batches so aren't interested in our small batch technology.

Bear in mind that all of this positive news came from people with an interest in telling positive news, and who have always talked a good game. I can't help but think that past events at this company are weighing on the share price and discouraging some serious investors from getting close to us. One risk is that the life sciences fund will be similarly discouraged and will walk away. I think this is a risk because, as it is presented to us, the technology is a no brainer, good in every respect: so where are the big investors? Why so wary?

Taking up your rights in the SPP is a calculated risk. From what I can see, the company has made slow but steady progress to this position over the last two years, and we're now close to seeing a big piece of the puzzle fall into place. Can the board pull it off? That's the question you have to answer when deciding on the SPP.

The board expects the SPP to fall short by a little, with the remainder to be placed to other investors. So, Rager and Syd, there should be plenty of shares for you to load up on.